期刊文献+

红细胞生成素刺激剂的临床应用进展 被引量:3

下载PDF
导出
摘要 健康肾脏生成的红细胞生成素(erythropoietin,EPO)是刺激骨髓生成红细胞的重要激素。未出生时的产EPO细胞存在于胚肝和胚肾,出生后逐渐转移到肾脏。肾小管和毛细血管内皮之间的管周间质细胞。
作者 陈源汉 史伟
出处 《中国血液净化》 2016年第3期129-131,共3页 Chinese Journal of Blood Purification
基金 国家临床重点专科建设项目
  • 相关文献

参考文献8

  • 1Obara N, Suzuki N, Kim K, et al. Repression via the GA- TA box is essential for tissue-specific erythropoietin gene expression[J]. Blood, 2008,111(10):5223-5232.
  • 2Eoehendoerfer GG, Chen SY, Mao F, et al. Design and chemical synthesis of a homogeneous polymer- modified erythropoiesis protein[J]. Science, 2003,299(5608):884- 887.
  • 3陈楠,钱家麒,梅长林,张爱华,邢昌赢,王莉,刘文虎,王梅,陈江华,刘必成,侯凡凡,陈香美,左力,史伟,于凌博,张怡.持续性促红细胞生成素受体激活剂治疗慢性肾脏病透析患者肾性贫血的疗效和安全性的开放、随机、对照、多中心研究[J].中华内科杂志,2012,51(7):502-507. 被引量:27
  • 4Macdougall IC, Rossert J, Casadevall N, et al. A pep- tide- based erythropoietin- receptor agonist for pure red-cell aplasia[J]. N Engl J Med, 2009,361(19):1848- 1855.
  • 5Macdougall IC, Provenzano R, Sharma A, et al. Peginesa- tide for anemia in patients with chronic kidney dis- ease not receiving dialysis[J]. N Engl J Med, 2013,368 (4):320-332.
  • 6Fishbane S, Schiller B, Locatelli F, et al. Peginesa- tide in patients with anemia undergoing hemodialysis [J]. N Engl J Med, 2013,368(4):307-319.
  • 7Bennett CL, Jacob S, Hymes J, et aI. Anaphylaxis and hy- potension after administration of peginesatide[J]. N Engl J Med, 2014,370(21):2055-2056.
  • 8Skali H, Parving HH, Parfrey PS, et al. Stroke in pa- tients with type 2 diabetes mellitus, chronic kidney disease, and anemia treated with Darbepoetin Alfa: the trial to reduce cardiovascular events with Aranesp therapy (TREAT) experience[J]. Circulation, 2011,124 (25):2903-2908.

二级参考文献18

  • 1FinkelsteinFO, Story K, Firanek C, et al.Health-related quality of life and hemoglobin levels in chronic kidney disease patients.Clin J Am Soc Nephrol, 2009,4:33-38.
  • 2PerlmanRL, Finkelstein FO, Liu L,et al.Quality of life in chronic kidney disease (CKD): a cross-sectional analysis in the Renal Research Institute-CKD study.Am J Kidney Dis, 2005,45:658-666.
  • 3WalkerAM, Schneider G, Yeaw J, et al.Anemia as a predictor of cardiovascular events in patients with elevated serum creatinine.J Am Soc Nephrol, 2006,17:2293-2298.
  • 4SilverbergD.Outcomes of anaemia management in renal insufficiency and cardiac disease.Nephrol Dial Transplant, 2003,18 Suppl 2:ii7-12.
  • 5LiS, Foley RN, Collins AJ.Anemia, hospitalization, and mortality in patients receiving peritoneal dialysis in the United States.Kidney Int, 2004,65:1864-1869.
  • 6Regidor DL, Kopple JD, Kovesdy CP, et al.Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients.J Am Soc Nephrol, 2006,17:1181-1191.
  • 7IV.NKFK/DOQI Clinical Practice Guidelines for Anemia of Chronic Kidney Disease: update 2000.Am J Kidney Dis, 2001,37(1 Suppl 1):S182-238.
  • 8Cameron JS.European best practice guidelines for the management of anaemia in patients with chronic renal failure.Nephrol Dial Transplant, 1999,14 Suppl 2:61-65.
  • 9Macdougall IC, Robson R, Opatrna S, et al.Pharmacokinetics and pharmacodynamics of intravenous and subcutaneous continuous erythropoietin receptor activator (C.E.R.A.) in patients with chronic kidney disease.Clin J Am Soc Nephrol, 2006,1:1211-1215.
  • 10SulowiczW, Locatelli F, Ryckelynck JP,et al.Once-monthly subcutaneous C.E.R.A.maintains stable hemoglobin control in patients with chronic kidney disease on dialysis and converted directly from epoetin one to three times weekly.Clin J Am Soc Nephrol, 2007,2:637-646.

共引文献26

同被引文献23

引证文献3

二级引证文献40

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部